JCAR015
Drug
Celgene Corporation
Total Payments
$469,773
Transactions
17
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $10,075 | 3 | 0 |
| 2018 | $459,697 | 14 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $466,950 | 15 | 99.4% |
| Consulting Fee | $2,800 | 1 | 0.6% |
| Food and Beverage | $22.50 | 1 | 0.0% |
Payments by Type
Research
$466,950
15 transactions
General
$2,823
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| JCAR015-ALL-Pivotal-1525 - The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia6 | Celgene Corporation | $278,989 | 0 |
| JCAR015-ALL-001 - A phase 2, open-label, multiple cohort, single-arm, multi-center trial to determine the safety, feasibility and efficacy of JCAR015 in adult subjects with B-cell acute lymphoblastic leukemia. | Celgene Corporation | $158,569 | 0 |
| 015002 - Long-Term Follow-up Protocol for Subjects Treated With JCAR015 | Celgene Corporation | $19,317 | 0 |
| Long-Term Follow-up Protocol for Subjects Treated With JCAR015 (15002) | Celgene Corporation | $5,250 | 0 |
| The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia6 (JCAR015-LTFU-15002) | Celgene Corporation | $1,825 | 0 |
Ad
Manufacturing Companies
- Celgene Corporation $469,773
Product Information
- Type Drug
- Total Payments $469,773
- Total Doctors 2
- Transactions 17
About JCAR015
JCAR015 is a drug associated with $469,773 in payments to 2 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $10,075 was paid across 3 transactions to 0 doctors.
The most common payment nature for JCAR015 is "Unspecified" ($466,950, 99.4% of total).
JCAR015 is associated with 5 research studies, including "JCAR015-ALL-Pivotal-1525 - The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia6" ($278,989).